Given the very limited data regarding ocular AEs under VEGFR-TKIs, we felt it was necessary to inform the scientific community about another case of corneal perforation in a patient affected by advanced RCC on therapy with a VEGFR-TKI, Cabozantinib. The gene discussed is KDR; the disease is renal cell carcinoma.